On June 16, 2021, Brains Bioceutical Corp. closed a US$31.9 million capital raise with DSM Venturing (the corporate venture arm of Royal DSM) and existing Brains shareholders. In addition, Brains has entered into an exclusive global partnership with Royal DSM with a view to unlocking the therapeutic potential of cannabinoids in early-stage drug development.
Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development and clinical trials. It is also one of the few manufacturers in commercial production in Europe with EU-GMDP certification, producing CBD API for both human and veterinary use within a MHRA licensed facility.
Cassels acted for Brains.